Related Experiment Videos

HLA antigens and progression of multiple sclerosis. Part II

Journal of Neurology
|January 1, 1983
PubMed

Insights

Human Leukocyte Antigen (HLA) types were studied in multiple sclerosis (MS) patients. The HLA-DR2 determinant was more frequent in patients with later MS onset but did not correlate with disease progression or IgG synthesis.

Area of Science:

  • Neuroimmunology
  • Human Genetics
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Human Leukocyte Antigen (HLA) genes are crucial for immune regulation and have been implicated in MS susceptibility.
  • Understanding the role of HLA in MS progression is vital for predicting disease course and developing targeted therapies.

Purpose of the Study:

  • To investigate the association between HLA-A, -B, -C, and -D alleles and the progression of multiple sclerosis.
  • To determine if specific HLA haplotypes correlate with disease onset age, clinical course, and intrathecal immunoglobulin G (IgG) synthesis.

Main Methods:

  • HLA typing (HLA-A, -B, -C, -D) was performed on 200 MS patients.
  • Disease progression, onset age, clinical course, and cerebrospinal fluid (CSF) parameters (IgG index, oligoclonal bands) were analyzed.
  • Statistical correlations were sought between HLA types and clinical/CSF findings.

Main Results:

  • No significant correlation was found between HLA haplotypes and MS progression rate or clinical disease course.
  • Patients with MS onset after age 31 were more likely to carry the HLA-DR2 determinant (P = 0.016).
  • While DR2 carriers showed a higher proportion of elevated IgG index or oligoclonal bands, this difference was not statistically significant compared to non-carriers.

Conclusions:

  • HLA haplotypes are not associated with the rate of multiple sclerosis progression or disease course.
  • The HLA-DR2 determinant may be linked to a later age of MS onset.
  • HLA-DR2 status does not significantly influence intrathecal IgG synthesis in MS patients.

Related Concept Videos